Doctors Recommend A New Complex Cancer Treatment – Part 3 of 3
Anthracyclines are functional in treating HER2-positive breast cancer, but have very toxic side effects that can lead to congestive heart failure and leukemia. Doctors found that 92 percent of 3,231 women treated with the changed combination chemo survived more than three years with no recurrence of their cancer. These results make the new combination a viable alternative to anthracycline-based chemotherapy, said head researcher Dr Dennis Slamon, director of clinical-translational research at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles.
So “It is going to be difficult to elaborate treatment regimens that have even better response rates than that,” said Slamon, who is also chief of hematology-oncology with UCLA’s department of medicine This study was supported by funds from Roche/Genentech. Slamon has served as an counsellor to both companies, including during the time period when the study was conducted kindle. Because the studies were presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.